Companies developing artificial intelligence-based platforms that enable the design of small-molecule and biologic drug candidates have been a focus of biopharma dealmaking in the past year. Companies developing artificial intelligence-based platforms that enable the design of small-molecule and biologic drug candidates have been a focus of biopharma dealmaking in the past year.
No takes yet. Share an insight, caveat, or question.
Biopharma Dealmakers (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: